Meeting
2019 ASCO Annual Meeting
Patient-reported outcomes (PROs) in IMmotion150: Atezolizumab (atezo) alone or with bevacizumab (bev) versus sunitinib (sun) in first-line metastatic renal cell carcinoma (mRCC).
Authors
Sumanta K. Pal
City of Hope National Medical Center, Duarte, CA
Sumanta K. Pal , David F. McDermott , Michael B. Atkins , Bernard Escudier , Brian I. Rini , Robert J. Motzer , Lawrence Fong , Richard Wayne Joseph , Stephane Oudard , Alain Ravaud , Sergio Bracarda , Cristina Suarez Rodriguez , Elaine Tat Lam , Toni K. Choueiri , Beiying Ding , Caroleen Quach , Kenji Hashimoto , Christina Schiff , Elisabeth Piault , Thomas Powles
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Genitourinary (Nonprostate) Cancer
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT01984242
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4515)
DOI
10.1200/JCO.2019.37.15_suppl.4515
Abstract #
4515
Poster Bd #
341
Abstract Disclosures
Similar Posters
Poster
2017 Genitourinary Cancers Symposium
A phase II study of atezolizumab (atezo) with or without bevacizumab (bev) versus sunitinib (sun) in untreated metastatic renal cell carcinoma (mRCC) patients (pts).
First Author: David F. McDermott
Poster
2024 ASCO Genitourinary Cancers Symposium
Health-related quality of life (HrQoL) of first-line treatments in metastatic renal cell carcinoma (mRCC): A network meta-analysis.
First Author: Oluseyi Abidoye
Poster
2019 ASCO Annual Meeting
Atezolizumab (atezo) + bevacizumab (bev) versus sunitinib (sun) in pts with untreated metastatic renal cell carcinoma (mRCC) and sarcomatoid (sarc) histology: IMmotion151 subgroup analysis.
First Author: Brian I. Rini
Poster
2019 Genitourinary Cancers Symposium
Outcomes of patients with metastatic clear cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
First Author: Amishi Yogesh Shah